drugset
drugset / Trial / NCT05206812

Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)

NCT05206812 ↗

Phase 2 Active not recruiting 25 enrolled Yonsei University
NaSingle-groupOpen-labelTreatment

Summary

This study is phase II, open label, clinical trial of durvalumab to identify immune dynamics in operable non-small cell lung cancer.

Timeline

Start
2022-09-01
Primary completion
2027-01
Completion
2028-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Durvalumab Monoclonal antibody 1500 mg Intravenous
Subject Durvalumab Monoclonal antibody 1500 mg/m2 Intravenous

Indications

non-small cell lung carcinoma